CA2390399A1 - Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes - Google Patents

Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes Download PDF

Info

Publication number
CA2390399A1
CA2390399A1 CA002390399A CA2390399A CA2390399A1 CA 2390399 A1 CA2390399 A1 CA 2390399A1 CA 002390399 A CA002390399 A CA 002390399A CA 2390399 A CA2390399 A CA 2390399A CA 2390399 A1 CA2390399 A1 CA 2390399A1
Authority
CA
Canada
Prior art keywords
cell
library
compound
reporter gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390399A
Other languages
English (en)
Inventor
Yves Blais
Pierre Rousseau
Benoit Leblanc
Rino N. Camato
Patricia Villain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENEKA BIOTECHNOLOGY Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002327581A external-priority patent/CA2327581A1/fr
Application filed by Individual filed Critical Individual
Priority to CA002390399A priority Critical patent/CA2390399A1/fr
Publication of CA2390399A1 publication Critical patent/CA2390399A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés et des produits permettant de déterminer, par des analyses en série, les voies d'activation transcriptionnelle utilisées par n'importe lequel des composés d'intérêt biologiquement actifs dans une cellule. Une banque de lignées cellulaires de recombinaison ou transgéniques a été élaborée afin de permettre l'identification de voies transcriptionnelles simultanées éventuellement utilisées par le composé. Chaque lignée cellulaire composant la banque a été mise au point par transfection stable de celle-ci par intégration rétrovirale, de manière à transporter un gène rapporteur sous le contrôle transcriptionnel d'un facteur de transcription particulier ou d'une famille de celui-ci endogène à la cellule hôte. Ceci peut être réalisé par régulation par un promoteur minimal et par un élément sensible au facteur de transcription (TF-RE) ou un tandem ou un concatémère de ceux-ci de l'expression du gène rapporteur. Dans sa forme complète, la banque rassemble un grand nombre de constructions de rapporteurs sensibles à des facteurs individuels, chacune de ces constructions pouvant être étudiées dans une large gamme de lignées cellulaires. Une telle approche permet une vue d'ensemble de l'activation de la transcription génique face à divers stimuli dans plusieurs environnements cellulaires. L'approche décrite dans cette invention et une approche améliorée par rapport aux approches au cas par cas. Un composé criblé contre une telle banque permet d'obtenir un profil de sélectivité pour un facteur de transcription donné et pour un type de cellule donné, lequel profil est utilisé pour sélectionner une éventuelle thérapie sélective adaptée.
CA002390399A 2000-12-27 2001-12-21 Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes Abandoned CA2390399A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002390399A CA2390399A1 (fr) 2000-12-27 2001-12-21 Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,327,581 2000-12-27
CA002327581A CA2327581A1 (fr) 2000-12-27 2000-12-27 Methodes et compositions pour etablir une bibliotheque de cellules modifiees genetiquement concue pour suivre l'activite transcriptionnelle de composes et de molecules
PCT/CA2001/001861 WO2002052039A2 (fr) 2000-12-27 2001-12-21 Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes
CA002390399A CA2390399A1 (fr) 2000-12-27 2001-12-21 Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes

Publications (1)

Publication Number Publication Date
CA2390399A1 true CA2390399A1 (fr) 2002-07-04

Family

ID=25682276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390399A Abandoned CA2390399A1 (fr) 2000-12-27 2001-12-21 Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes

Country Status (1)

Country Link
CA (1) CA2390399A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913871A (zh) * 2017-05-17 2020-03-24 西雅图儿童医院(Dba西雅图儿童研究所) 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913871A (zh) * 2017-05-17 2020-03-24 西雅图儿童医院(Dba西雅图儿童研究所) 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
CN110913871B (zh) * 2017-05-17 2024-02-23 西雅图儿童医院(Dba西雅图儿童研究所) 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法

Similar Documents

Publication Publication Date Title
Kang et al. A self-enabling TGFβ response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells
AU776576B2 (en) Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6458538B1 (en) Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
Starck et al. A general approach to detect protein expression in vivo using fluorescent puromycin conjugates
WO2002052039A2 (fr) Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes
EP2985347B1 (fr) Procédé de détection de la stabilité de protéines et ses utilisations
King Chemistry or biology: which comes first after the genome is sequenced?
US20100099096A1 (en) Compositions and Methods for Identifying Factors Affecting Protein Stability
NZ524186A (en) Methods for discovering a combination of compounds and non-chemical entities that can affect a biological property of living cells
US20130260386A1 (en) Nucleic acid construct systems capable of diagnosing or treating a cell state
CA2390399A1 (fr) Procedes permettant de selectionner et de produire des compositions et des composes pharmaceutiques selectifs au moyen d'une banque de cellules genetiquement modifiees sensible aux facteurs de transcription; constructions genetiques et banque associes
Sun et al. Homeobox transcription factor MNX1 is crucial for restraining the expression of pan-neuronal genes in motor neurons
US20030143547A1 (en) Method for identifying multiple activated transcription factors
US20030148287A1 (en) Libraries and kits for detecting transcription factor activity
US20240141328A1 (en) Assay for Massive Parallel RNA Function Perturbation Profiling
US20040137488A1 (en) Methods for identifying the activity of gene products
US20030219723A1 (en) Compositions and methods for screening and identifying anti-HCV agents
Lee et al. Using pooled miR30-shRNA library for cancer lethal and synthetic lethal screens
US7186505B1 (en) Expression systems and methods for detecting and isolating polypeptides regulating signal transduction pathways
JP2004215624A (ja) 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット
KR20060118705A (ko) 혈청반응성 프로모터를 가진 리포터 아데노바이러스를 이용한 고속생리활성 물질의 검색 방법
AU5407701A (en) Methods for identifying combinations of entities as therapeutics

Legal Events

Date Code Title Description
FZDE Discontinued